RapidSelection™ EarlyAccess measures live cancer cells against a predetermined panel of 20 FDA-approved cancer drugs.
This option requires that you share the treatment outcome data to help Travera build additional clinical evidence.
Turnaround time: 2 days from sample collection
Total drugs tested: 20 FDA-approved
Sample types: Tissue, Malignant Fluids


